Zoetis (ZTS) Q2 FY25 earnings call

Earnings call· Jun 2025 (Q2 FY25)· Health Care· Aug 5, 2025

Source: earnings call transcript

Zoetis delivered strong broad-based growth in Q2 FY25, driven by its diversified portfolio and innovation engine, leading to a raise in full-year guidance. While Librela adoption faced headwinds, the company is investing in education and studies to accelerate its trajectory. The company remains confident in its ability to adapt to competitive and macroeconomic challenges, including tariffs, through disciplined execution and cost management.

You’re reading a preview. Opening the full call uses 1 concall credit.

ZTS operating KPIs by quarter

ZTS operating KPIs stated on its earnings calls, by fiscal quarter
KPI	Dec 2024 Q4 FY24	This call Jun 2025 Q2 FY25	Change vs prior quarter
Patients Librela	1.2M+ Librela, now entering its second year in the market, generated $53 million, growing 21% on the quarter and reaching more than 1.2 million patients. Source: earnings call transcript	1M And today, we are reaching just 1 million of them. Source: earnings call transcript	—

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.